The Multiple System Atrophy (MSA) Therapeutics Market is estimated to be valued at USD 149.6 million in 2025 and is projected to reach USD 230.2 million by 2035, registering a compound annual growth rate (CAGR) of 4.4% over the forecast period.
| Metric | Value |
|---|---|
| Multiple System Atrophy (MSA) Therapeutics Market Estimated Value in (2025 E) | USD 149.6 million |
| Multiple System Atrophy (MSA) Therapeutics Market Forecast Value in (2035 F) | USD 230.2 million |
| Forecast CAGR (2025 to 2035) | 4.4% |
The Multiple System Atrophy (MSA) Therapeutics market is expanding steadily due to growing clinical awareness, increased diagnostic capabilities, and the emergence of targeted treatment approaches for this rare and debilitating neurodegenerative disorder. Increased funding for rare disease research and orphan drug development has paved the way for pharmaceutical innovation, particularly in neurodegeneration-focused pipelines. Investor communications and neurological science journals have highlighted that rising patient advocacy and earlier symptom identification are improving diagnosis timelines, which in turn support earlier therapeutic intervention.
As healthcare systems improve neurological care infrastructure, demand for precision diagnostics and supportive treatment protocols is growing. Additionally, the involvement of academic institutions in translational research and clinical trials is enabling faster progression from discovery to treatment.
Industry news has emphasized the urgency among biotech companies to address the unmet needs of MSA patients through combination therapies, symptomatic management, and neuroprotective agents These developments are expected to shape the long-term trajectory of this market by facilitating earlier intervention and expanding access to emerging treatment modalities.
The market is segmented by Type and Diagnosis and region. By Type, the market is divided into Parkinsonian and Cerebellar. In terms of Diagnosis, the market is classified into Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The Parkinsonian type is expected to account for 63.7% of the Multiple System Atrophy Therapeutics market revenue share in 2025, establishing it as the dominant type segment. This leadership has been influenced by the higher prevalence of Parkinsonian features among MSA patients, which mimic idiopathic Parkinson’s disease and result in a larger diagnosed population under this subtype.
Clinical findings and neurology-focused journals have documented that Parkinsonian MSA manifests with more recognizable motor symptoms, such as bradykinesia and rigidity, which lead to earlier clinical presentation and faster therapeutic engagement. Additionally, drug developers have concentrated their research on this subtype due to the overlap in symptomatic pathways with Parkinson’s disease, allowing for repurposing and faster regulatory traction.
Health system data also indicates that patients with Parkinsonian MSA are more likely to receive pharmacological and supportive therapies earlier in the disease course These factors, along with clinical trial prioritization, have contributed to the continued dominance of this segment in the MSA therapeutics landscape.
The Magnetic Resonance Imaging (MRI) diagnosis segment is projected to hold 41.5% of the Multiple System Atrophy Therapeutics market revenue share in 2025, making it the leading diagnostic segment. This position has been achieved due to MRI’s superior ability to identify hallmark structural brain changes associated with MSA, including atrophy in the putamen, cerebellum, and brainstem. Neurology case studies and diagnostic guidelines have consistently emphasized MRI’s role in distinguishing MSA from other parkinsonian syndromes, especially during early symptom onset.
Advanced imaging protocols have been refined to improve diagnostic sensitivity, allowing for better tracking of disease progression. Furthermore, the non-invasive nature and wide availability of MRI technology in both hospital and specialty neurology centers have made it the preferred initial imaging choice.
Industry updates also point to increased use of MRI in clinical trials for patient stratification and monitoring of therapeutic efficacy These technical and practical advantages have established MRI as a cornerstone in the diagnostic workflow of MSA.
The Multiple System Atrophy (MSA) Market is expected to gain market growth in the forecast period of 2025 to 2035. Latest market analysis by FMI the market is to grow at a CAGR of 4.4% in the above-mentioned forecast period.
The Covid-19 pandemic has had a significant effect on the market. The COVID-19 pandemic has relatively little of an impact on the world market for multiple system atrophy (MSA) therapeutics. The epidemic has had a direct influence on the supply and demand of medications, as well as on businesses and financial markets. It has also disturbed the distribution system.
The global multiple system atrophy (MSA) therapeutics markets grew at a CAGR of 4.0% from 2020 to 2025, as per Future Market Insights, a provider of market research and competitive intelligence.
The multiple system atrophy market share is expected to grow significantly, mainly due to increasing cases of neurodegenerative disorders. The multiple system atrophy market is expected to witness advancement in the upcoming years due to a new type of drug launch. Due to patent protection loss, new players are expected to enter the multiple system atrophy during the forecast years.
Increase in the Frequency of Neurodegenerative Diseases, Which Is One of the Primary Reasons Driving the Growth Market
The major market growth factors include the rising prevalence of neurodegenerative disorders, increasing awareness among the global population, and a strong product pipeline for neurological disease treatment. With the increasing global population and an average lifespan, the prevalence of multiple system atrophy is on the rise.
People affected by MSA experience dysfunction of the autonomic nervous system, which commonly manifests as orthostatic hypotension, impotence, loss of sweating, dry mouth and urinary retention, and incontinence.
According to the National Library of Medicine - MSA is considered an orphan disease with an annual incidence rate of 0.1-3 per 100,000 depending on age and geographic region.
Increase in government support and drug approval to widen the market scope.
In addition, increasing government support and increasing awareness about neurodegenerative disorders fuel the market growth. The rise in expenditure on healthcare in developing countries and the growth in patient awareness of the use of nerve monitoring devices provide new opportunities for market players. Awareness regarding the clinical benefits of nerve monitoring drives the sales of multiple system atrophy therapeutics market in the forecasting period.
For instance, in September 2024 - Alterity Therapeutics biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases announced the approval of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The approval of this IND authorizes Alterity to conduct its Phase 2 clinical trial in the USA.
Inadequate reimbursement policies may hamper global market growth.
The lack of government and hospital reimbursement policies for treating neurodegenerative illnesses such as Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease restricts the market growth. On the other hand, patients are switching to generics due to the lower cost, which is expected to limit the use of patented drugs.
The exceptionally high price is expected to stifle market growth by limiting access to quality treatment in middle and low-income countries.
High failure rates in clinical trials and research & development (R&D): Clinical trial and research and development (R&D) failure rates have always been a significant challenge within the multiple system atrophy therapeutics market. Companies are constantly investing in Research and Development to develop treatment options for neurodegenerative diseases, but very few treatments are currently approved.
Growing Prevalence of MSA in Region to Drive the Market Growth
North America accounts for the market share of 45.3% of multiple system atrophy therapeutics in 2025 and is likely to lead the multiple system atrophy market during the forecast period.
Growing medication demand, high prices, increased Research and Development investment, and favorable health reimbursement policies are driving the growth of the multiple system atrophy market in North America.
MSA is affecting potentially 15,000 to 50,000 Americans, including men and women and all racial groups. Symptoms of the disease appear in a person’s 50s and advance rapidly over the course of 5 to 10 years, with progressive loss of motor function and eventual confinement to bed. People with MSA often develop pneumonia in the later stages of the disease and may suddenly die from cardiac or respiratory issues.
Increased R&D Investment and Favourable Health Reimbursement Policies are Driving The Growth of The Market In Europe
Europe is expected to be the most significant neurodegenerative disease market. Factors affecting the growth of the market studied are the increasing number of MSA disorders, and research and development by private and government organizations focused on developing treatments for such diseases.
The growth of the European multiple system atrophy therapeutics market during the forecast period is attributed to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government. Europe to exhibit a CAGR of 4.2% in the multiple system atrophy therapeutics market during the forecast period.
For instance, in August 2025, Alterity Therapeutics a biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in the United Kingdom.
| UK | 4.2% |
|---|---|
| India | 3.8% |
| South Korea | 4.0% |
| China | 4.1% |
| USA | 4.4% |
PET Scan Segment remains dominant among other types
Based on diagnosis multiple system atrophy market is segmented into Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others. Among these, the PET scan segment dominated the market in 2025 with a revenue share of 34.6%.
A PET scan (positron emission tomography, which allows doctors to see how organs and tissues are functioning) is sometimes used to see if the metabolic function is reduced in specific parts of the brain. DaTscan can assess the dopamine transporter in a part of the brain called the striatum and can help physicians determine if the condition is caused by a dopamine system disorder; however, this test cannot differentiate between MSA and Parkinson’s disease. Individuals with MSA typically do not have sustained improvement in their symptoms with levodopa (a drug used to treat Parkinson’s disease), a finding that often supports the diagnosis of MSA.
How do New Entrants Contribute to the Multiple System Atrophy (MSA Therapeutics Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the multiple system atrophy therapeutics market.
Some of the start-ups in the multiple system atrophy therapeutics market include-
Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.
The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2025 to 2035 |
| Expected Market Value (2025) | USD 137.3 Million |
| Projected Forecast Value (2035) | USD 211.1 Million |
| Base Year for Estimation | 2025 |
| Historical Data | 2020 to 2025 |
| Forecast Period | 2025 to 2035 |
| Quantitative Units | Revenue in USD Million & CAGR from 2025 to 2035 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Type, Diagnosis, Regions |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC, South Africa, Israel |
| Key Companies Profiled | Biohaven Pharmaceuticals, Inc.; Sumitomo Dainippon Pharma Co., Ltd.; AstraZeneca plc; Theravance Biopharma, Inc.; Merck & Co.; Neuropore Therapies Inc; Newron Pharmaceuticals SpA; ProMIS Neurosciences Inc; Stealth BioTherapeutics Corp; Chelsea Therapeutics International, Ltd. |
| Customization | Available Upon Request |
The global multiple system atrophy (MSA) therapeutics market is estimated to be valued at USD 149.6 million in 2025.
The market size for the multiple system atrophy (MSA) therapeutics market is projected to reach USD 230.2 million by 2035.
The multiple system atrophy (MSA) therapeutics market is expected to grow at a 4.4% CAGR between 2025 and 2035.
The key product types in multiple system atrophy (MSA) therapeutics market are parkinsonian and cerebellar.
In terms of diagnosis, magnetic resonance imaging (MRI) segment to command 41.5% share in the multiple system atrophy (MSA) therapeutics market in 2025.
Explore Similar Insights
Multiple System Atrophy (MSA) Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
